Hallie Coltin , M.D.,C.M. , FRCPC , M.Sc.
    Hallie Coltin
    Research Axis
    Immune Diseases and Cancer Axis
    Research Theme
    Cancers: mechanisms, new therapeutic approaches and disease outcomes

    514-345-4931 ext. 117325


    • Pediatric Hematologist-Oncologist, Neuro-Oncology and Retinoblastoma Programs, CHU Sainte-Justine (2022)
    • Assistant Professor, Department of Pediatrics, University of Montreal (2022)
    • Clinician-Investigator, Immune Diseases and Cancer Research Axis, CHU Sainte-Justine Research Center (2022)


    Research fellowship, Garron Family Cancer Centre, University of Toronto, Hospital for Sick Children (2021-2022)

    Pediatric neuro-oncology fellowship, University of Toronto, Hospital for Sick Children (2020-2021)

    M.Sc. Clinical Epidemiology, University of Ottawa (2021)

    Clinician Investigator Program, University of Ottawa (2021)

    Pediatric hematology-oncology fellowship, University of Ottawa, CHEO (2016-2018)

    Pediatric hematology-oncology fellowship, McGill University, Montreal Children’s Hospital (2015-2016)

    Pediatrics residency, University of British Columbia, BC Children’s Hospital (2011-2015)

    Doctorate of Medicine, McGill University (2007-2011)

    Research Interests

    As a pediatric neuro-oncologist and clinician-scientist, Dr. Coltin’s research focuses on understanding and improving the long-term medical and functional outcomes of pediatric central nervous system (CNS) tumour survivors and their family members. Specifically, she leverages population-based health administrative data to study the burden and predictors of adverse outcomes such as hearing loss, strokes, disability, mental health, and early mortality. She is a member of the Cancer in Young People in Canada (CYP-C) Management Committee.

    Research Topics

    • Pediatric neuro-oncology and oncology
    • Retinoblastoma
    • Clinical epidemiology
    • Long-term outcomes in pediatric cancer survivors
    • Health services research
    • Linkage studies 

    Career Summary

    Dr. Hallie Coltin is a Staff Neuro-Oncologist and Clinician Investigator at the CHU Sainte-Justine and an Assistant Professor at the Faculty of Medicine at the University of Montreal. She completed medical school at McGill University, pediatrics residency at BC Children’s Hospital, and fellowship training in pediatric hematology-oncology at the Montreal Children’s Hospital and the Children’s Hospital of Eastern Ontario (CHEO). She completed a Master’s of Science in Clinical Epidemiology through the Clinician Investigator Program at the University of Ottawa, which was supported by a CIHR (Canadian Institutes of Health Research) graduate scholarship. She then pursued a two-year combined clinical and research fellowship in pediatric neuro-oncology at the Hospital for Sick Children which was supported by a training grant from the Charles-Bruneau Foundation and a research fellowship grant from the Garron Family Cancer Centre. She is currently supported by a salary award from ENRICH (Empowering Next-generation Researchers In perinatal and Child Health).


    Coltin Lab

    Awards and Distinctions

    • 2022: Conquer Cancer Endowed Merit Award, American Society of Clinical Oncology (ASCO)
    • 2021: BMO Financial Group Oncology Fellowship Award, Hospital for Sick Children
    • 2020: Young Investigator Award, International Society of Paediatric Oncology (SIOP)
    • 2020: Merit Award, American Society of Clinical Oncology (ASCO)
    • 2019: Junior Investigator Grant Panel Travel Award, Canadian Cancer Society Research Institute
    • 2018: Excellence Scholarship, Graduate and Postdoctoral Studies, University of Ottawa 
    • 2018: Master’s Graduate Scholarship, Canadian Institutes of Health Research (CIHR)
    • 2018: Ontario Graduate Scholarship, University of Ottawa (declined)
    • 2018: Second Place Student Research Day Quick Talks, School of Epidemiology and Public Health, University of Ottawa
    • 2017: Graduate Studies Admission Scholarship, University of Ottawa (declined)


    Coltin H, Brundler MA, Ulster A, Griffiths B, Milne M, Venier R. Meet the Experts Panel, Canadian Retinoblastoma Research Advisory Board Research Symposium, Toronto, ON, 2023

    Coltin H. Long-term outcomes of pediatric central nervous system tumour survivors, Pediatric Ontario Group of Ontario Multi-Disciplinary Symposium on Childhood Cancer, Toronto, ON, 2022 (invited keynote speaker)

    Coltin H. Long-term outcomes of pediatric central nervous system tumour survivors, CHU Sainte-Justine Research Centre Scientific Conference, Montreal, QC, 2022

    Coltin H. A health services research approach to study the long-term outcomes of pediatric medulloblastoma and ependymoma survivors, Hospital for Sick Children Haematology/Oncology Divisional Rounds, Toronto, ON, 2022

    Coltin H. Subgroup and subtype specific outcomes in adult medulloblastoma, Garron Family Cancer Centre Virtual Cancer Research Week, Toronto, ON, 2021


    Coltin H, Pequeno P, Liu N, et al. The Burden of Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in Ontario, Canada [published online ahead of print, 2023 Jan 25]. J Clin Oncol. 2023; JCO2202466. doi:10.1200/JCO.22.02466

    Arbour G, Ellezam B, Weil AG, Cayrol R, Vanan MI, Coltin H, Larouche V, Erker C, Jabado N, Perreault S. Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature. Neurooncol Adv. 2022 Nov 19;4(1): vdac174. doi: 10.1093/noajnl/vdac174

    Coltin H, Perreault S, Larouche V, et al. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series. Pediatr Blood Cancer. 2022;69(8): e29633. doi:10.1002/pbc.29633

    Coltin H, Ramaswamy V. Molecular and clinical correlates of medulloblastoma subgroups: A narrative review. Glioma 2021; 4:92-9. DOI: 10.4103/glioma.glioma_18_21

    Goudie C, Witkowski L, Cullinan N, Reichman L, Schiller I, Tachdjian M, Armstrong L, Blood KA, Brossard J, Brunga L, Cacciotti C, Caswell K, Cellot S, Clark ME, Clinton C, Coltin H, Felton K, Fernandez CV, Fleming AJ, Fuentes-Bolanos N, Gibson P, Grant R, Hammad R, Harrison LW, Irwin MS, Johnston DL, Kane S, Lafay-Cousin L, Lara-Corrales I, Larouche V, Mathews N, Meyn MS, Michaeli O, Perrier R, Pike M, Punnett A, Ramaswamy V, Say J, Somers G, Tabori U, Thibodeau ML, Toupin AK, Tucker KM, van Engelen K, Vairy S, Waespe N, Warby M, Wasserman JD, Whitlock JA, Sinnett D, Jabado N, Nathan PC, Shlien A, Kamihara J, Deyell RJ, Ziegler DS, Nichols KE, Dendukuri N, Malkin D, Villani A, Foulkes WD. Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncol. 2021 Dec 1;7(12):1806-1814. doi: 10.1001/jamaoncol.2021.4536

    Coltin H, Rapoport A, Baxter NN, et al. Locus-of-care disparities in end-of-life care intensity among adolescents and young adults with cancer: A population-based study using the IMPACT cohort. Cancer. 2022;128(2):326-334. doi:10.1002/cncr.33926

    Coltin H, Sundaresan L, Smith KS, et al. Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathol. 2021;142(5):859-871. doi:10.1007/s00401-021-02358-4

    Baroni LV, Sundaresan L, Heled A, Coltin H, Pajtler KW, Lin T, Merchant TE, McLendon R, Faria C, Buntine M, White CL, Pfister SM, Gilbert MR, Armstrong TS, Bouffet E, Kumar S, Taylor MD, Aldape KD, Ellison DW, Gottardo NG, Kool M, Korshunov A, Hansford JR, Ramaswamy V. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021 Aug 2;23(8):1360-1370. doi: 10.1093/neuonc/noab034

    Bennett J, Erker C, Lafay-Cousin L, Ramaswamy V, Hukin J, Vanan MI, Cheng S, Coltin H, Fonseca A, Johnston D, Lo A, Zelcer S, Alvi S, Bowes L, Brossard J, Charlebois J, Eisenstat D, Felton K, Fleming A, Jabado N, Larouche V, Legault G, Mpofu C, Perreault S, Silva M, Sinha R, Strother D, Tsang DS, Wilson B, Crooks B, Bartels U. Canadian Pediatric Neuro-Oncology Standards of Practice. Front Oncol. 2020 Dec 22;10:593192. doi: 10.3389/fonc.2020.593192

    Paquette K, Coltin H, Boivin A, Amre D, Nuyt AM, Luu TM. Cancer risk in children and young adults born preterm: A systematic review and meta-analysis. PLoS One. 2019;14(1):e0210366. Published 2019 Jan 4. doi:10.1371/ journal.pone.0210366


Grow Beyond our wildest dreams

With the support of donors like you, at the heart of the Grow Beyond campaign, we are leading healthcare teams towards the opportunities offered by science and new technologies, so that every child, no matter where in Quebec, has access to the unique expertise and know-how of CHU Sainte-Justine. Together, let's join forces for their future.

Grow Beyond with us.

Contact Us

514 345-4931


© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security


Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine